|
1
|
Makishima M, Okamoto AY, Repa JJ, et al:
Identification of a nuclear receptor for bile acids. Science.
284:1362–1365. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Urizar NL, Liverman AB, Dodds DT, et al: A
natural product that lowers cholesterol as an antagonist ligand for
FXR. Science. 296:1703–1706. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hollman DA, Milona A, van Erpecum KJ and
van Mil SW: Anti-inflammatory and metabolic actions of FXR:
insights into molecular mechanisms. Biochim Biophys Acta.
1821:1443–1452. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Matsubara T, Li F and Gonzalez FJ: FXR
signaling in the enterohepatic system. Mol Cell Endocrinol.
368:17–29. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Porez G, Prawitt J, Gross B and Staels B:
Bile acid receptors as targets for the treatment of dyslipidemia
and cardiovascular disease. J Lipid Res. 53:1723–1737. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sinal CJ, Tohkin M, Miyata M, Ward JM,
Lambert G and Gonzalez FJ: Targeted disruption of the nuclear
receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell.
102:731–744. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gardmo C, Tamburro A, Modica S and
Moschetta A: Proteomics for the discovery of nuclear bile acid
receptor FXR targets. Biochim Biophys Acta. 1812:836–841. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kemper JK: Regulation of FXR
transcriptional activity in health and disease: Emerging roles of
FXR cofactors and post-translational modifications. Biochim Biophys
Acta. 1812:842–850. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu Y, Ma Z, Zhang Z, et al: Yin Yang 1
promotes hepatic steatosis through repression of farnesoid X
receptor in obese mice. Gut. 63:170–178. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang F, Huang X, Yi T, Yen Y, Moore DD and
Huang W: Spontaneous development of liver tumors in the absence of
the bile acid receptor farnesoid X receptor. Cancer Res.
67:863–867. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Modica S, Murzilli S, Salvatore L, Schmidt
DR and Moschetta A: Nuclear bile acid receptor FXR protects against
intestinal tumorigenesis. Cancer Res. 68:9589–9594. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim I, Morimura K, Shah Y, Yang Q, Ward JM
and Gonzalez FJ: Spontaneous hepatocarcinogenesis in farnesoid X
receptor-null mice. Carcinogenesis. 28:940–946. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Y, Song X, Valanejad L, et al: Bile
salt export pump is dysregulated with altered farnesoid X receptor
isoform expression in patients with hepatocellular carcinoma.
Hepatology. 57:1530–1541. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Duran-Sandoval D, Mautino G, Martin G, et
al: Glucose regulates the expression of the farnesoid X receptor in
liver. Diabetes. 53:890–898. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim MS, Shigenaga J, Moser A, Feingold K
and Grunfeld C: Repression of farnesoid X receptor during the acute
phase response. J Biol Chem. 278:8988–8995. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Gong W, Dai S, et al:
Downregulation of human farnesoid X receptor by miR-421 promotes
proliferation and migration of hepatocellular carcinoma cells. Mol
Cancer Res. 10:516–522. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ohno T, Shirakami Y, Shimizu M, et al:
Synergistic growth inhibition of human hepatocellular carcinoma
cells by acyclic retinoid and GW4064, a farnesoid X receptor
ligand. Cancer Lett. 323:215–222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He N, Park K, Zhang Y, Huang J, Lu S and
Wang L: Epigenetic inhibition of nuclear receptor small heterodimer
partner is associated with and regulates hepatocellular carcinoma
growth. Gastroenterology. 134:793–802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Y, Xu P, Park K, Choi Y, Moore DD
and Wang L: Orphan receptor small heterodimer partner suppresses
tumorigenesis by modulating cyclin D1 expression and cellular
proliferation. Hepatology. 48:289–298. 2008. View Article : Google Scholar
|
|
20
|
Hollander MC, Blumenthal GM and Dennis PA:
PTEN loss in the continuum of common cancers, rare syndromes and
mouse models. Nat Rev Cancer. 11:289–301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Warde N: Prostate cancer: loss of PTEN
promotes progression of prostate cancer in an androgen-independent
manner. Nat Rev Urol. 8:4122011. View Article : Google Scholar : PubMed/NCBI
|
